Opinion
Video
Author(s):
Looking to the future treatment landscape in prostate cancer, the panel provides closing thoughts on the trajectory of the utilization of PSMA-PET imaging and the unmet needs it might address.
Real-world studies underline safety, efficacy of radium-223 in mCRPC
Dr. Murphy on increasing diversity in cancer clinical trials
Radium-223 re-treatment is safe in patients with mCRPC
Dr. Schwen on focal therapies for prostate cancer
Race subgroup analysis points to clinical benefit of darolutamide in nmCRPC
STOPCAP: ARPIs benefit younger patients with mHSPC